Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nathan Waldron

Critical Care Medicine Jacksonville, FL Medical Doctor

NPI 1578839817 CMS profile 5704719

4500 San Pablo Rd S, Jacksonville, FL 32224

Open in the dashboard

General payments

$17,349

23 records reported · program years 2019–2025

Research payments

$3,100

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$67,173 paid to institutions, not to them · program year 2019

Through program year 2025, Nathan Waldron of Jacksonville, FL is reported in the CMS Open Payments database as having received $17,349 across 23 general payments and $3,100 in research payments paid to them. Separately, studies naming them as principal investigator received $67,173 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $121 1
2024 Research $2,500 1
2023 General $3,000 1
2022 General $2,839 9
2022 Research $600 1
2021 General $20 1
2020 General $1,211 2
2019 General $10,158 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nathan Waldron
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Nathan Waldron were reported at $121. Among 445 Critical Care Medicine profiles paid that year, the median was $97 and the middle half received between $33 and $255.

Show as a table
Year Nathan Waldron Critical Care Medicine median Middle half National median
2019 $10,158 $103 $29–$256 $163
2020 $1,211 $60 $22–$164 $114
2021 $20 $115 $30–$249 $132
2022 $2,839 $97 $27–$196 $149
2023 $3,000 $104 $31–$245 $160
2024 $0 $93 $28–$268 $164
2025 $121 $97 $33–$255 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $11,339 9 payments
  2. AbbVie, Inc. $5,839 10 payments
  3. Haemonetics Corporation $121 1 payment
  4. Edwards Lifesciences Corporation $39 2 payments
  5. Mallinckrodt Hospital Products Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $13,300 5 payments
  2. Travel and Lodging $2,121 7 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,200 1 payment
  4. Food and Beverage $728 10 payments
Products named General payments · program years 2019–2025
  1. TEG6s HEMOSTASIS SYSTEM $121 1 payment
  2. HemoSphere $20 1 payment
  3. FloTrac Sensor $18 1 payment
  4. OFIRMEV $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Zynex Monitoring Solutions $2,500 1 payment
  2. AbbVie, Inc. $600 1 payment

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$41,733

Medicare's payments for the services billed

Medicare patients

211

Average age 72

Services billed

339

92 women, 119 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 58%
Arthritis 48%
Atrial fibrillation 45%
Chronic kidney disease 45%
Heart failure 43%
Diabetes 39%
COPD 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

25 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record